BioTie Therapies (6, BIOTIE) is a biotechnology company which develops pharmaceutical products based on proprietary technology.  It is co-developing “bioheparin” as an antithrombotic drug, and is involved in the development of antiangiogenic molecules derived from bacterial polysaccharide K5.  It has facilities and experience for tumor growth inhibition studies.